** Shares of biotech firm Oncolytics Biotech ONCY.O rise 2% to $0.97
** Co says it will meet the FDA on April 16 to discuss a possible approval path for its experimental anal cancer drug pelareorep
** This rare cancer starts in anal canal and few options exist once standard treatments fail
** Co says it plans to propose a single‑arm study combining pelareorep with a type of cancer immunotherapy in patients who have no approved alternatives
** Earlier study showed about a 30% tumor response rate lasting around 17 months, compared with 10%–14% and about 9.5 months for existing options, co says
** Including session's move, stock up ~12% YTD
(Reporting by Sahil Pandey in Bengaluru)
((Sahil.Pandey@thomsonreuters.com))